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Abstract 
 
Background:  Infectious mononucleosis (IM) and vitamin D deficiency are both risk 
factors for multiple sclerosis (MS).   
 
Objective:  We wished to establish if IM in the winter months when vitamin D levels 
are low may be a greater risk factor for MS than IM in the summer months. 
 
Methods:  We identified all patients with MS diagnosed aged 16 to 60 in a large 
primary care database in the United Kingdom and matched each by age, sex, 
general practice and observation period with up to six controls.  We identified a 
coded diagnosis of IM prior to the index date (date of diagnosis).  Logistic regression 
was used to calculate the odds ratio for prior IM exposure in cases versus controls 
and for winter versus summer exposure in cases and controls with prior IM 
exposure. 
 
Results:  Based on 9,247 cases and 55,033 matched controls (246 and 846 with 
prior IM respectively), IM was associated with the development of MS (OR 1.77, 
95%CI 1.53-2.05) but there was no evidence that IM in the winter as opposed to 
summer was associated with developing MS (OR 1.09, 95%CI 0.72-1.66). 
 
Conclusion:  We found no evidence that the season of IM influences the risk of 
subsequent MS. 
 
Keywords:  multiple sclerosis, infectious mononucleosis, seasons, risk factors   
 Introduction 
 
Increasing latitude (Ascherio and Munger, 2007a) and infection with Epstein Barr Virus 
(EBV) (Ascherio and Munger, 2007b, Almohmeed et al., 2013, Holmøy, 2008) are both 
known risk factors for multiple sclerosis (MS).  The geographical variation in MS is 
thought to be at least partly due to lower vitamin D levels because of lower sunlight 
exposure at higher latitudes.  This is supported by evidence that lower serum vitamin 
D levels are associated with a higher risk of developing MS (Munger et al., 2006) 
although vitamin D replacement has not yet been shown to improve clinical outcomes 
(James et al., 2013). 
 
Patients with MS are significantly more likely to be sero-positive for anti-EBV 
antibodies than controls (95% vs 86%), indicating a higher risk of any prior infection 
with EBV (Almohmeed et al, 2013).  They  are also more likely to have had 
symptomatic infectious mononucleosis (glandular fever) due to first exposure to EBV 
in adolescence rather than childhood (2-14% in MS patients vs 0.7-7% in controls, 
depending on method of ascertainment) (Handel et al., 2010, Lossius et al., 2010, 
Marrie et al, 2000). These rates are much lower than the rate of EBV sero-positivity, 
which is consistent with the fact that most EBV exposure is in early life when it is 
relatively asymptomatic Individuals with MS also display an unusual immune response 
to EBV, with significantly higher anti-EBV antibody titres present for many years prior 
to the onset of symptoms compared to EBV sero-positive controls who do not develop 
MS (Levin et al., 2005). 
 
Vitamin D has multiple effects on immune function such as increasing the production 
of the anti-inflammatory cytokine IL-10, inducing T-regulatory cells, and promoting 
tolerance to self-antigens (Aranow, 2011).   IL-10 plays an important role in the immune 
response to latent EBV infection (Marshall et al., 2003, Marshall et al., 2007).  It has 
been suggested that vitamin D modulates the immune response to EBV (Holmøy, 
2008) so that vitamin D deficiency at the time of infection with EBV could increase the 
risk of subsequently developing MS (Ascherio and Munger, 2007b, Holmøy, 2008).  If 
a vitamin D dependent immune response to EBV is indeed related to the risk of 
subsequently developing MS, infectious mononucleosis in the winter months when 
serum vitamin D levels are at their lowest would be hypothesised to be more strongly 
associated with MS than infectious mononucleosis in the summer.  A single case-
control study of 1660 MS patients and 3050 controls found no relationship between 
the risk of MS and season of infectious mononucleosis (Lossius et al., 2014) but this 
relied on patient self-reporting of infectious mononucleosis and has not been 
replicated.    
 
We aimed to: (a) confirm whether MS patients in the United Kingdom (UK) are more 
likely to have had previous infectious mononucleosis than controls; (b) assess whether 
infectious mononucleosis in winter (defined by either months with lowest recorded 
vitamin D levels [December-May] (Hypponen and Power, 2007) or lowest sunlight 
[October-March] (UK Climate Period) is a stronger risk factor for MS than infectious 
mononucleosis occurring in summer. 
 
Materials and Methods 
The Clinical Practice Research Datalink [CPRD] (CPRD homepage) holds routinely-
collected, quality-assured, anonymised clinical data from primary care on over 10 
million patients in the UK. We requested data for all MS cases aged 16 years and over 
with a first coded diagnosis of multiple sclerosis or, if no MS code, a first prescription 
of a MS disease modifying agent from 1990-2010 (see supplementary tables e1 and 
e2 for codes used).  All patients aged 16-60 who were registered on the CPRD for a 
minimum of two years and had a first coded diagnosis of MS were identified. Cases 
were matched with up to six control patients by age, gender, general practice and 
duration of observation in the CPRD prior to the date of MS diagnosis (index date). 
 
We identified the date of onset of MS as either the date of first presentation with a 
symptom or diagnosis (e.g. optic neuritis) consistent with MS (see supplementary table 
e3 for codes), or if there were no such symptoms recorded, the date a diagnosis of 
MS was made. 
 
Patients were defined as having had infectious mononucleosis if they had a coded 
diagnosis of infectious mononucleosis, or had a “positive” or “abnormal” infectious 
mononucleosis test result prior to the onset of MS (see supplementary tables e4 and 
e5 for codes). Patients who had a recorded diagnosis of infectious mononucleosis but 
who had received a negative infectious mononucleosis test result within seven days 
of the diagnosis being made were regarded as having not had infectious 
mononucleosis. The time of year of glandular fever was identified from the date of 
entry of the infectious mononucleosis diagnosis or positive test result code.  
 
To assess whether MS patients were more likely to have had previous infectious 
mononucleosis than their matched controls, we calculated an odds ratio (OR) with 
conditional logistic regression.  We then analysed with non-conditional logistic 
regression only those cases and controls with a recorded date of infectious 
mononucleosis to assess whether infectious mononucleosis in December to May was 
associated with an increased risk of MS than infectious mononucleosis occurring 
during June to November, controlling for age at index date, sex and geographical 
region.  Statistical analysis was performed in StatsDirect v2.5.6.  Sample size 
calculations were based on the rates of infectious mononucleosis in MS cases and 
controls previously reported in the CPRD database (Marrie et al., 2000).  One 
thousand three hundred MS cases and 7,700 controls would demonstrate that MS is 
associated with a 2.3 fold increase in the odds of infectious mononucleosis (5% 
significance level, 80% power), as found in a previous meta-analysis (Thacker et al., 
2006).  One hundred and sixty MS patients and 160 controls would be required to 
detect a two-fold increase in the odds of winter infectious mononucleosis in MS 
patients (5% significance, 80% power).  The project was reviewed and accepted by 
the Independent Scientific Advisory Committee for MHRA database research but did 
not require ethics approval as the data were all anonymised. 
 
Results 
After exclusions (Figure 1), analysis was performed on 9,247 cases and 55,033 
matched controls, mean index age 41 years, 71% female.  The median observation 
period in the GPRD was 24.5 years (interquartile range 15.2 to 35.8).  In 13% MS 
patients there was a date of first attack prior to the date of diagnosis (mean age 36 
years).  The mean ages of infectious mononucleosis was 21.7 (SD 9.3) and 19.4 (SD 
7.5) years in patients and controls respectively and the median time from the diagnosis 
of infectious mononucleosis to the diagnosis of MS was 15.0 years (interquartile range 
9.2 to 22.8 years).  Prior infectious mononucleosis occurred in 246/9,247 (2.7%) MS 
patients and 846/55,033 (1.5%) controls and conditional logistic regression showed 
prior infectious mononucleosis exposure was more common in MS cases than controls 
(OR 1.77, 95%CI 1.53-2.05). 
 
1,092 patients had a prior diagnosis of infectious mononucleosis of whom 128/246 
(52%) cases and 363/846 (43%) controls were excluded because the date of infection 
was unclear (Table 1). The difference in proportions of excluded data was significant 
(p=0.013).  The case and control groups with prior infectious mononucleosis were 
similar in terms of age at index date (both 34 years) and sex (75% and 78% female 
respectively).  Exposure to infectious mononucleosis during winter was not associated 
with a higher risk of MS than exposure during summer months, whether defined by 
low vitamin D levels (OR 1.09, 95%CI 0.72-1.66) or sunlight (OR 0.96, 95%CI 0.63-
1.45).  Including only MS patients with a date of first attack did not alter the results, 
although only 19 MS patients with infectious mononucleosis were included (vitamin D 
OR 0.61, 95%CI 0.20, 2.34, sunlight OR 0.84, 95%CI 0.30, 2.34). 
 
Table 1: Season of infectious mononucleosis in cases and controls 
 
 MS Cases Controls Total 
 Sunlight* Vit D† Sunlight* Vit D†  
Prior IM 246 846 1,092 
Winter 60 70 250 270 340 
Summer 58 48 233 213 261 
Season unclear 128 363 491 
No prior IM coded 9,001 54,187 63,188 
Total 9,247 55,033 64,280 
 
MS – multiple sclerosis; IM – infectious mononucleosis 
* winter = October to March inclusive 
† winter = December to May inclusive 
 
Discussion 
We confirmed that previous infectious mononucleosis significantly increases the risk 
of MS, in keeping with a recent meta-analysis (19,390 cases, 16,007 controls from 18 
individual studies), which showed a relative risk of MS with prior infectious 
mononucleosis of 2.17 (Handel et al., 2010).  This study adds weight to this evidence, 
and benefited from a substantially larger study population than most previous 
individual case-control studies.  In terms of exposure to infectious mononucleosis in 
MS and controls our results were similar to a smaller study using an earlier version of 
the CPRD database, which found that 2.2% of MS patients and 0.7% controls had 
been exposed (Marrie et al., 2000). 
 
Previous infectious mononucleosis and increasing latitude are both risk factors for MS, 
and it had been hypothesised that vitamin D deficiency at higher latitudes may 
modulate the immune response to EBV, such that the risk of subsequently developing 
MS is increased. However, similar to Lossius et al. (2014), we did not find that 
infectious mononucleosis in winter, when serum vitamin D levels are at their lowest, 
was more strongly associated with MS than infectious mononucleosis during summer.  
Although the odds ratios were about one, the confidence intervals were wide.  
Therefore, although we have excluded a two-fold increase in the odds of MS with 
winter exposure, there may be a smaller but still significant association.  Larger studies 
would be needed to detect this.  Lossius et al. (2014) found higher overall rates of prior 
infectious mononucleosis exposure than we did in both MS patients (14%) and 
controls (7.2%).  This may be because they overestimated exposure because of 
inaccurate self-reporting by patients and we underestimated exposure due to missed 
reporting in the CPRD.   
 
The strength of this study was the use of a large unselected national primary care 
database with medical confirmation (not self-reporting) of the diagnoses of MS and 
infectious mononucleosis.  The main limitations were due to issues with the coded 
data. 87% of patients lacked a clear date for their first attack of MS, which meant that 
it is possible that infectious mononucleosis had occurred after the onset of their MS.  
However, this is unlikely given that the mean age of diagnosis of infectious 
mononucleosis was 21 years in MS patients, well before the usual age of onset of MS.  
Many patients with infectious mononucleosis also had to be excluded because they 
lacked an accurate date of diagnosis (three had no date recorded and 488 had 1st 
January recorded, which is likely to have been an automatically generated date when 
only the year of infectious mononucleosis infection, rather than the full date, had been 
entered into the CPRD database).  Exclusion of these infectious mononucleosis cases 
resulted in reduced power in our study but we do not believe it introduced a bias as 
the excluded cases were roughly evenly distributed amongst MS patients and controls.  
It would have required the missing 128 MS patients to have a 2:1 ratio in 
winter:summer infectious mononucleosis exposure to generate a statistically 
significant odds ratio if the missing controls had a similar winter:summer ratio as the 
analysed controls.  We also inferred vitamin D status from the season of exposure as 
we did not have measurements of actual vitamin D status at the time of infectious 
mononucleosis exposure, which would be difficult to ascertain. 
 
We found no effect of seasonality of infectious mononucleosis on the risk of developing 
MS.  If vitamin D does interact with EBV infection to alter the risk of MS, it may be that 
the immunoregulatory activity of vitamin D plays a more important role during latent 
EBV infection, rather than during the initial infection. 
 
In conclusion, this case-control study confirmed the findings of earlier studies that 
previous infectious mononucleosis is a risk factor for MS. However, there was no 
evidence of an association between the season of infectious mononucleosis infection 
and subsequent risk of MS.  It would be useful to corroborate our findings in other 
large scale case-control or cohort studies with more detailed timing of infectious 
mononucleosis and the onset of MS. 
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Figure legend 
 
Figure 1:  Study flow diagram 
 
Figure footnotes:  
CPRD = Clinical Practice Research Database;  
MS = multiple sclerosis; 
IM = infectious mononucleosis. 
 
 
 
